Form 4: Halozyme Therapeutics CFO Reports Stock Transactions

Nicole LaBrosse, CFO of Halozyme Therapeutics, reports the vesting and settlement of restricted and performance stock units, along with associated tax withholding obligations.

Summary

• Nicole LaBrosse, the SVP and CFO of Halozyme Therapeutics, reported several transactions involving the company's common stock.
• On February 15, 2025, Ms. LaBrosse acquired 1,254 shares of common stock through the vesting of restricted stock units and disposed of 741 shares to cover tax withholding obligations at a price of $58.29 per share.
• On February 16, 2025, she acquired 17,409 shares through the vesting of performance stock units, 5,093 shares through restricted stock units, and 5,329 shares through restricted stock units.
• She also disposed of 9,400, 2,742 and 2,869 shares respectively to cover tax obligations at $58.29 per share.
• Following these transactions, Ms. LaBrosse directly owns 28,813 shares of Halozyme Therapeutics common stock and 10,658 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reflects routine stock transactions related to executive compensation.

Positives

• The vesting of RSUs and PSUs indicates that Ms. LaBrosse is meeting performance metrics or time-based vesting requirements.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions. They are closely watched by investors to gauge management's sentiment and alignment with shareholder interests.

Comparison to Industry Standards

• Executive compensation packages often include a mix of salary, stock options, restricted stock units, and performance-based incentives.
• The vesting schedules and tax withholding practices observed in this filing are typical for publicly traded companies.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they involve the issuance of new shares and the subsequent sale of shares to cover tax obligations.

Key Dates

Keywords

Halozyme Therapeutics, Nicole LaBrosse, Stock Transactions, Form 4, Restricted Stock Units, Performance Stock Units, CFO, Vesting, Tax Withholding